Rush Hymenoptera venom immunotherapy:: A safe and practical protocol for high-risk patients

被引:93
|
作者
Sturm, G [1 ]
Kränke, B [1 ]
Rudolph, C [1 ]
Aberer, W [1 ]
机构
[1] Graz Univ, Dept Environm Dermatol & Allergy, A-8036 Graz, Austria
关键词
honeybee venom; Hymenoptera venom allergy; rush immunotherapy; side effects; yellow jacket venom;
D O I
10.1067/mai.2002.129124
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Hymenoptera venom immunotherapy in allergic patients is a well-established treatment modality for the prevention of systemic anaphylactic reactions caused by insect stings. A variety of therapy regimens exists, from conventional to rush and ultrarush modalities that operate on continuous or intermittent schedules. Objective: The aim of this study was to report the 8-year experience with our rush venom immunotherapy regimen in predominantly high-risk patients and to compare data on safety and convenience with the results of 26 studies published from 1978 to 2001. Methods: One hundred one patients allergic to bee, yellow jacket, or hornet venom were treated with rush Hymenoptera venom immunotherapy. Diagnosis and selection of patients for venom immunotherapy were carried out according to the recommendations of the European Academy of Allergology and Clinical Immunology. We used a 4-day regimen, and the incidence and nature of systemic reactions (SRs) were documented. Fifty-two patients were treated with honeybee venom, and 49 were treated with yellow jacket venom. Results: One hundred (99%) patients reached the maintenance dose. We observed 8 injection-related SRs (0.47% of all injections given) in 7 (6.9%) patients. The number of SRs was higher in patients treated with bee venom extract (12%) compared with in patients receiving yellow jacket venom extract (2%). There was no significant difference in the risk of SRs between female and male patients. The incidence of SRs was considerably lower than the average of 17.8% reported in the literature. Conclusion: With a rush immunotherapy regimen over a time period of 8 years in predominantly high-risk patients, the incidence of SRs was low, despite the high number of patients with bee venom allergy, who are more likely to have side effects. Epinephrine as rescue medication was never necessary, and the regimen proved to be safe and convenient for both the patients and the medical staff.
引用
收藏
页码:928 / 933
页数:6
相关论文
共 50 条
  • [1] Venom Immunotherapy in High-Risk Patients: The Advantage of the Rush Build-Up Protocol
    Rosman, Yossi
    Confino-Cohen, Ronit
    Goldberg, Arnon
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2017, 174 (01) : 45 - 51
  • [2] Rush Hymenoptera venom immunotherapy is efficacious and safe
    Pasaoglu, G.
    Sin, B. A.
    Misirligil, Z.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2006, 16 (04) : 232 - 238
  • [3] Tolerance of rush protocol of hymenoptera venom immunotherapy: a case report
    Hernandez-Mondragon, L. O.
    Del Rio-Navarro, B. E.
    Del Rio-Chivardi, J.
    Navarrete-Rodriguez, E. M.
    Lievano-Perez, M. A.
    Rosas-Vargas, M. A.
    De Baro-Alvarez, P.
    ALLERGY, 2013, 68 : 494 - 494
  • [4] Venom Immunotherapy in High Risk Patients; The Advantage of a Rush Build-up Protocol
    Rosman, Yossi
    Confino-Cohen, Ronit
    Hershko, Alon
    Lachover-Roth, Idit
    Goldberg, Arnon
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB193 - AB193
  • [5] Safety of Hymenoptera venom rush immunotherapy
    Laurent, J
    Smiejan, JM
    BlochMorot, E
    Herman, D
    ALLERGY, 1997, 52 (01) : 94 - 96
  • [6] Safety of rush hymenoptera venom immunotherapy
    Brockow, K
    Ring, J
    ALLERGY, 2004, 59 (11) : 1233 - 1233
  • [7] Rush Hymenoptera Venom Immunotherapy in Thai Children
    Kerddonfak, S.
    Manuyakorn, W.
    Kamchaisatian, W.
    Sasisakulporn, C.
    Teawsomboonkit, W.
    Benjaponpitak, S.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S242 - S242
  • [8] A five-day safe and practical protocol for Venom Immunotherapy
    Koti, I
    Mellios, A.
    Koulouris, S.
    Chliva, C.
    Makris, M.
    Kalogeromitros, D.
    ALLERGY, 2008, 63 : 510 - 511
  • [9] Safety of a ultra-rush dose-increase protocol for hymenoptera venom immunotherapy
    Bucher, C
    Schwager, S
    Schmid-GRendelmeier, P
    Wuthrich, B
    ALLERGY, 2002, 57 : 76 - 76
  • [10] SAFETY OF HYMENOPTERA VENOM IMMUNOTHERAPY ADMINISTRATED IN RUSH REGIMEN
    Riano-Avanzini, Teresa
    Barra-Castro, Alicia
    Gonzalez-de-Olano, David
    Antolin-Amerigo, Dario
    De-la-Hoz-Caballer, Belen
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB59 - AB59